**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
**C07D 413/14, 417/14, 401/14, A61K 31/44, C07D 413/04, 417/04, 235/24, 401/04, 471/04 // (C07D 471/04, 235:00, 235:00, 221:00)**

A1

(11) International Publication Number: **WO 00/05232**

(43) International Publication Date: 3 February 2000 (03.02.00)

(21) International Application Number: PCT/IB99/01211

(22) International Filing Date: 28 June 1999 (28.06.99)

(30) Priority Data:
9815880.1 21 July 1998 (21.07.98) GB

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for all designated States except GB US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KEMP, Mark, Ian [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). PALMER, Michael, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). SANNER, Mark, Allen [US/US]; Pfizer Inc., Central Research, Eastern Point Road, Groton, CT 06340 (US). WYTHES, Martin, James [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
*With international search report.*

(54) Title: HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES



(I)

(57) Abstract

Compounds of the formula (I) wherein A is unbranched C3–C5 alkylene optionally substituted by C1–C6 alkyl; X is O, S, NH or N(C1–C6 alkyl); Y is O, S, NH or N(C1–C6 alkyl); R is a C–linked, 4– to 6–membered ring, non–aromatic, heterocyclic group containing one nitrogen heteroatom, said group being optionally substituted by 1, 2 or 3 substituent(s) each independently selected from C1–C6 alkyl, C2–C6 alkenyl, C3–C7 cycloalkyl, aryl, het, –CO2(C1–C6 alkyl), –CO(het), –CONR5R6 and –CO(aryl), said alkyl and alkenyl being optionally substituted by 1 or 2 substituent(s) each independently selected from C3–C7 cycloalkyl, aryl, het, –O(aryl), –O(C1–C2 alkylene) aryl, –CO(het), –CONR5R6 and –CO(aryl); are inhibitors of rotamase enzymes in particular FKBP–12 and FKBP–52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders involving nerve damage.